AGP Executive Report
Last update: 37 minutes agoCancer Drug Update (China): China’s NMPA approved pirtobrutinib (Jaypirca) for CLL/SLL across all therapy lines, including patients previously treated with covalent BTK inhibitors, backed by BRUIN CLL-313 and CLL-314 data. Oncology Research (China/Global): A symposium discussion highlights progress and practical testing approaches for targeting KRAS in cholangiocarcinoma, where mutation patterns shape drug development. Cardiovascular & Hormones: A JAMA Internal Medicine target-trial emulation found menopausal hormone therapy started in perimenopause/early postmenopause was linked to lower cardiovascular disease risk, supporting a “timing” effect. Diabetes Care (US, relevant to China patients): The FDA approved Lilly’s once-weekly basal insulin efsitora alfa-gobe (Onswik) for type 2 diabetes, aiming to cut injection burden. Clinical Trials Ops: The FDA opened applications for an Expedited IND Pilot to speed first-in-human studies, addressing delays when trials move overseas. Public Health Tech & Safety: Alabama reached a settlement with TikTok/ByteDance over teen safety, requiring usage limits and stronger age verification. Trade & Medical Supply Context: The US and China agreed on tariff cuts for about $60B in non-sensitive goods, including medical devices and personal-care items, with implementation tied to domestic procedures.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
